Asia-Pacific Active Pharmaceutical Ingredient Market By Method of Synthesis (Biological and Synthetic) By Source (Contact Manufacturing Organizations and In-House Manufacturing) By Therapeutic Application (Cardiovascular Diseases, Anti-diabetic Drugs, Oncology Drugs, Neurological Disorders, Musculoskeletal Disorders, Others) By Molecule Type (Small and Large) By Potency (Low and High) By Drug Type
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationAsia-Pacific Active Pharmaceutical Ingredient Market By Method of Synthesis (Biological and Synthetic) By Source (Contact Manufacturing Organizations and In-House Manufacturing) By Therapeutic Application (Cardiovascular Diseases, Anti-diabetic Drugs, Oncology Drugs, Neurological Disorders, Musculoskeletal Disorders, Others) By Molecule Type (Small and Large) By Potency (Low and High) By Drug Type
Asia Pacific active pharmaceutical ingredient market is projected to boom in the upcoming five years while exhibiting an impressive CAGR. An over the counter (OTC) or prescription drug's produces desired medical effects because of the active pharmaceutical ingredient (API) present in it. Some medications, including combination therapy, contain a number of APIs that may work differently or address various symptoms. For instance, the main ingredient in Tylenol, acetaminophen, is a well-known example of an API. Hence API is the key component of a formulation through which the formulation produces a desired medical effect.
China is a major active pharmaceutical ingredient producer in the Asia Pacific region which helps in fulfilling the global demand of API. China has been exporting tons of APIs to different parts of the globe for drug production. The sudden outbreak and spread of pandemic COVID-19 and imposition of lockdown and restriction on trade in order to curb the virus highlighted the importance of dependency on China for APIs. As a result of this, the Government of India launched a Production Linked Incentive Scheme under which more than 50 APIs would be indigenously produced in India to reduce dependency on China and make India self sufficient and emerge out as a leader in API supply and production. The emergence of India as a API producer and China being a leader will create lucrative opportunities for the growth of Asia Pacific Active Pharmaceutical Ingredient Market in the coming years.
The development in the production of active pharmaceutical ingredients (APIs) as well as the increased incidence of chronic diseases including cancer and cardiovascular conditions are both responsible for the market expansion of active pharmaceutical ingredients. Government regulations that are supportive of API manufacturing, together with shifting geopolitical conditions, are accelerating market growth. The market for active pharmaceutical ingredients (APIs) is also expected to grow as a result of increased technological advancements improving the capabilities and boosting manufacturing skills of market participants. Moreover, the market for active pharmaceutical ingredients (APIs) is also expected to have more growth potential as research funding for API development continues to rise. Hence, the market is expected to grow at significant rate during the forecast period.
Demand for Precision Medicines
The demand for precision medicines in the Asia Pacific is expected to grow at a significant rate during the forecast period owing to healthcare awareness, along with the adoption of advanced diagnosis methods. Additionally, the rising incidence of chronic diseases and the region's expanding population have increased the demand for sequencing technologies. Further, precision medicine is gaining more attention from the healthcare system, clinicians, governments, and pharmaceutical companies. FDA approvals and advancements in precision medicines have boosted market expansion during the forecast period. Additionally, the market is expanding due to the growing acceptance of precision medicine, which is fueling increased research and development for the selection of the most effective treatment based on molecular analysis of tumors and preclinical studies. This in turn is anticipated to drive market expansion.
Increasing Disease Burden
According to the Ministry of Internal Affairs and Communications, as of September 15, 2022, the total population of Japan fell by 820,000 over the last year. At the same time, the number of seniors aged 65 years and above increased by 60,000 for a record total of 36.27 million. This is an increase by 0.03% from that in 2021.
Market Segmentation
Asia Pacific Active Pharmaceutical Ingredient Market is segmented
Recent Developments
·
Market Players
Cipla Limited, Pfizer, Inc., Dr. Reddy's Laboratories Ltd., Symbiotica Speciality Ingredients Sdn. Bhd., ScinoPharm Taiwan Ltd, Zhejiang Hisun Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., AbbVie Inc., AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Lupin Limited, Nanjing Pharmaceutical Factory Co. Ltd., among others are some of the key players operating in the Asia Pacific Active Pharmaceutical Ingredient Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · Method of Synthesis · Source · Therapeutic Application · Molecule Type · Potency · Drug Type |
| Country scope | China; India; Japan; South Korea; Taiwan; Vietnam; Philippines; Indonesia; Malaysia; Australia |
| Key companies profiled | Cipla Limited, Pfizer, Inc., Dr. Reddy's Laboratories Ltd., Symbiotica Speciality Ingredients Sdn. Bhd., ScinoPharm Taiwan Ltd, Zhejiang Hisun Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., AbbVie Inc., AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Lupin Limited, Nanjing Pharmaceutical Factory Co. Ltd. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy